VEGFA and neoplasm: In xenograft models of rhabdomyosarcoma, bevacizumab, an anti-VEGF mAb, has been demonstrated to be capable of inhibiting tumor growth and metastases and enhancing tumor sensitivity to radiation [24,25], thus possessing a therapeutic potential for refractory rhabdomyosarcoma.